Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20818274 | 0.98 | HTR2C (0.49) | HTR2CSLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL4610755 | 0.87 | ESR1 (0.43) | SLC6A2SLC6A4SLC6A3ESR1 | |
| SCHEMBL4610704 | 0.87 | ESR1 (0.43) | SLC6A2SLC6A4SLC6A3ESR1 | |
| SCHEMBL23579155 | 0.84 | KDM4E (0.44) | SLC6A2SLC6A4SLC6A3ESR1 | |
| SCHEMBL23516016 | 0.79 | SLC6A4 (0.38) | SLC6A2SLC6A4SLC6A3ESR1 | |
| SCHEMBL13874310 | 0.79 | SLC6A2 (0.45) | HTR2CSLC6A2SLC6A4SLC6A3CYP11B2 | |
| SCHEMBL11360247 | 0.79 | SLC6A2 (0.42) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11641397 | 0.78 | MC4R (0.44) | HTR2CSLC6A2SLC6A3 | |
| SCHEMBL11363222 | 0.77 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3GABRA1CYP11B2 | |
| SCHEMBL15920349 | 0.77 | CHRM3 (0.48) | SLC6A2SLC6A4SLC6A3CYP11B2SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | HTR2C 489/4885SLC6A2 332/4885SLC6A4 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.